Skip to content

News

21st July 2026

Merakris Therapeutics Awarded NIH Direct-to-Phase II SBIR Grant to Advance MTX-001 for Diabetic Foot Ulcers

17th June 2026

Merakris Therapeutics Awarded U.S. Department of Veterans Affairs Federal Supply Schedule Contract, Expanding Federal Market Access for Dermacyte® AC Matrix Amniotic Membrane Allograft

2nd June 2026

FDA Grants Fast Track Designation to Merakris’ MTX-001, Opening Potential Accelerated Path to Market for Venous Leg Ulcer Therapy

14th April 2026

Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model

7th April 2026

Merakris Therapeutics Provides FDA Update and Reports Interim Findings for MTX-001 in Venous Leg Ulcers

Top